Skip to main content

Comparing policies that limit pharmacy out-of-pocket expenses in the commercial fully-insured market

ByGabriela Dieguez, Jennifer Carioto, and Sally Maraldo
9 September 2020

In recent years, several states have implemented policies in the commercial fully-insured market that attempt to limit patient out-of-pocket (OOP) expenses for pharmacy benefits. This report examines key considerations for states, payers and patients for a range of policies, including the potential impact on member premiums and OOP costs for patients that rely on specialty drugs.

This article was commissioned by Bristol Myers Squibb.


About the Author(s)

Jennifer Carioto

Sally Maraldo

We’re here to help